The National Assembly criticized how the Cancer Disease Deliberation Committee has been undermining the purpose of the Risk-Sharing Agreement system that waives submission of PE evaluation data and disapproved reimbursement of anticancer drugs and rare disease treatments.

The committee has not allowed reimbursement of these drugs that have already been granted marketing authorization from the Ministry of Food and Drug Safety for lacking Phase III trial data, although the drugs cannot conduct Phase III trials.

On the 13th, Rep. Ki-Yoon Kang of the People Power Party claimed so while referring to the data submitted by the National Health Insurance Service.

According to the